Pharmaceuticals company Indoco Remedies announced Q1FY24 results: Revenues of Indoco Remedies grew by 5% at Rs 413.2 crore, as against Rs 394.9 crore in Q1FY23. EBIDTA to net sales for Q1FY24 is 15.2% at Rs 62.9 crore, compared to 18.1 % at Rs71.3 crore in Q1FY23. Profit After Tax is at Rs 25.7 crore, compared to Rs 37.5 crore in Q1FY23. Commenting on the results, Aditi Panandikar, Managing Director, Indoco Remedies said, “Our first quarter results demonstrate good growth in API business, complemented by steady performance in the Domestic Formulation business. We remain optimistic for the rest of the year and are committed to building and further strengthening our position in the market”. Result PDF